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ABSTRACT
The aim of this study was to reconsider the biological characteristics of epithelioid 
malignant peritoneal mesothelioma (E-MpM) in the light of new concepts about 
epithelial mesenchymal transition and mesenchymal epithelial reverse transition 
(EMT/MErT) and the role of epigenetic reprogramming in this context. To this end we 
profiled surgical specimens and derived cells cultures by a number of complementary 
approaches i.e. immunohistochemistry, immunofluorescence, in situ hybridization, 
biochemistry, pluripotent stem cell arrays, treatments with cytokines, growth factors 
and specific inhibitors.
The analyses of the surgical specimens showed that i) EZH2 is expressed 
throughout the spectrum of MpM, ii) that E-MpM (including the high-grade 
undifferentiated form) are characterised by c-MYC and miRNA 17-5p expression, 
and iii) that progression to sarcomatoid MpM is dictated by EMT regulators. They also 
showed that E-MpM expressed c-MET and are enriched in E- and P-cadherins- and 
VEGFR2-expressing CSCs, thus strongly supporting a role for MErT reprogramming in 
endowing E-MpM tumour cells with stemness and plasticity, and hence with a drug 
resistant phenotype. The cell culture-based experiments confirmed the stemness 
traits and plasticity of E-MpM, and support the view that EZH2 is a druggable target 
in this tumor.
INTRODUCTION
Epithelial-mesenchymal transition (EMT) and 
mesenchymal-epithelial reverse transition (MErT) play 
crucial roles in embryogenesis, wound healing and cancer 
progression/metastases [1]. They are highly dynamic and 
tightly controlled processes that involve transcription factors, 
chromatin reorganisation factors, surface receptors and 
adhesion molecules [2, 3]. The activation of EMT makes 
cancer cells highly plastic [4], and enable non-cancer stem 
cells to acquire the traits of cancer stem cells (CSCs) [5].
Two recent studies [6, 7] have challenged the field 
of EMT research by introducing the concept of hybrid 
EMT. Both studies suggest that cells that undergo partial 
EMT, i.e. cells co-expressing epithelial and mesenchymal 
markers, are more plastic and have an high degree of 
stemness sustained by cell-cell adhesion compared to fully 
transited cells. This new view implies that cells with a 
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hybrid phenotype can exploit a wider repertoire of survival 
strategies thus making it easier to evade cell death and 
anti-cancer treatments.
Malignant peritoneal mesothelioma (MpM) is a 
heterogeneous, aggressive tumour mainly caused by 
exposure to asbestos. It has been shown that all three 
types of asbestos are the most potent micro-enviromental 
inducers of MErT by means of an epigenetic process [8] or 
direct interaction with mesothelial cells [9]. MpMs express 
markers such as calretinin, cytokeratin 5/6 and podoplanin 
[10, 11], which are routinely used for diagnosis, and 
markers that have been more recently described such as 
VEGFR2 [12] and c-MET [13], or more widely explored 
in pre-clinical settings such as E-cadherin [14] and c-MYC 
[15].
MErT can be initiated by many signalling effectors 
[16], including the hepatocyte growth factor/scatter factor 
(HGF/SF)-mediated activation of c-MET in mesenchymal 
cells [17, 18]. It has been reported that, in addition to 
mediating intracellular cohesion, E-cadherin participates 
in regulating stemness [19–21], and the same is true for 
c-MYC [22, 23]. The recently described co-expression 
of E- and P-cadherin is particularly interesting as it has 
been reported to be a marker of stemness [24] or related to 
poor prognosis [25], and can be seen in the hybrid state of 
EMT/MErT [6, 7, 24].
It has been suggested that EMT is a significant 
morphological feature of malignant mesothelioma 
[25], and that aberrant polycomb-group (PcG) protein 
expression contributes to the pathogenesis of MpM [26]. 
We here propose a model of MpM in which the epithelioid 
variant (E-MpM), the most frequently encountered, at this 
site has the characteristics of MErT, and displays features 
of reprogramming with involvement of c-MYC, E- and 
P-cadherins and VEGFR2 as CSC regulators. E-MpMs 
may progress toward the undifferentiated high-grade (HG-
MpM) variant or a sarcomatous MpM (S-MpM), which is 
characterised by a change in immunophenotypical make 
up from the pluripotent OMSK (OCT4, c-MYC SOX2, 
and KLF4) marker c-MYC to the TWIST and SLUG 
EMT regulators. The PcG protein EZH2, which acts 
as a catalytic subunit in polycomb repressive complex 
2 (PRC2) and is shared by the methylation signatures 
of DNA and histone marks [27] emerges as a possible 
druggable target.
RESULTS
Our working hypothesis was that the phenotypical 
reversion of EMT (MErT) characterises the epithelial 
variant of peritoneal mesothelioma (E-MpM), and 
that this variant is plastic and has some of the traits of 
CSCs. To address this hypothesis, we analysed surgical 
specimens (17 E-MpMs, 2 HG E-MPM and 2 S-MpMs, 
Table 1) obtained from 21 untreated patients, using an 
integrated approach including immunohistochemistry 
(IHC), immunofluorescence, in situ hybridization (ISH), 
biochemistry and human pluripotent cell array. Cultured 
E-MpM tumour cells derived from the specimens were 
then used to confirm in vivo observation on stemness and 
plasticity by challenging them with cytokines and growth 
factors as well as small drugs (bevacizumab, sunitinib and 
GSK 126).
Surgical specimen analyses
Comparison of mesothelium and E-MpM expression 
profiles
Immunohistochemical analysis revealed that 
VEGFR2 and c-MET were expressed by the E-MpM 
specimens and mesothelium (Table 1 and Figure 1), 
in line with recent reports [12, 13], and the same was 
true of the pleiotropic marker c-MYC [22, 23, 28]. In 
the mesothelium, E-cadherin expression was faint and 
heterogeneous, whereas the EZH2 catalytic unit of PRC2 
[26], which has been reported to be expressed at low levels 
in normal cells [26, 29], was undetectable and Slug was 
negative (Supplementary Figure S1). With the exception 
of the undetectable EZH2, non-activated mesothelium 
seems to bear the basic machinery exploited by E-MpMs.
Immunoprofiles of the surgical specimens of MpM 
variants
EZH2 was expressed by the entire spectrum of 
MpM surgical specimens, although to different extents 
(Table 1 and Figure 1). The loss of INI1-mediated EZH2 
upregulation [30] was excluded by IHC (not shown). 
Unlike that of EZH2, the expression of OMSK cocktail-
related c-MYC transcription factor (TF) [22], the receptor 
tyrosine kinases (RTKs) c-MET and VEGFR2, and the 
adhesion molecule E-cadherin segregated with the E-MpM 
variant (Table 1 and Figure 1).
In terms of cell immunostaining distribution, c-MET 
expression was mainly restricted to cell membranes, 
whereas the expression of VEGFR2 was both membranous 
and cytoplasmic, thus suggesting that it may play a non-
canonical role. The expression of both markers was 
confirmed by ISH at RNA level (Supplementary Figure 
S2). E-cadherin showed membrane reactivity, in line 
with its role in promoting pluripotency by means of cell-
to-cell adhesion [19, 21, 31]. The percentage of nuclei 
immunolabelled by the specific c-MYC and EZH2 
antibodies was similar in most of the E-MpM specimens, 
with an increase paralleling that of Ki-67 restricted to cases 
#16 and #17 (Table 1, Figure 1). This finding suggests that 
these two cases may represent an intermediate point in the 
spectrum of progression toward the HG/undifferentiated 
form of E-MpM (see below).
The S-MpM specimens (cases #20 and 21, Table 1) 
showed the loss of E-cadherin as well as c-MYC, VEGFR2 
and c-MET and were enriched in cells expressing the 
SLUG (Figure 1) and TWIST (not shown) nuclear TFs, 
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with a large percentage of nuclei decorated by EZH2 and 
Ki-67 (Figure 1).
The immunophenotypical analysis highlighted the 
fact that not all E-MpMs progress to S-MpMs, but there 
is a type of upgraded form of E-MpMs that retains a 
immunoprofile more close to E-MpM (cases #18 and #19, 
Table 1, Figure 1). The increase in EZH2 in HG MpMs 
is consistent with the reported increase in the level of 
TGFbeta (see below and Figure 5), its acknowledged role 
in maintaining CSCs [32] and the decreased expression 
of E-cadherin [33]. Taken together, these findings suggest 
that c-MYC or EMT regulators respectively concur 
in MErT and EMT via the EZH2 chromatin modifier. 
The c-MYC findings are in line with its role as a core 
Table 1: IHC results
VEGFR2 exp/act MET exp/act c-MYC SLUG TWIST EZH2 E-Cad
1 Omentum +/na +/na + - - - +/-
2 Omentum +/na +/na + - - - +/-
3 Omentum +/na +/na + - - - +/-
#1 E-MPM 1Δ +/- +/+ + - - + +
#2 E-MPM 2Δ +/- +/+ + - - + +
#3 E-MPM 3Δ +/- +/+ + - - + +
#4 E-MPM 4 + + + - - + +
#5 E-MPM 5 + + + - - + +
#6 E-MPM 6Δ + + + - - + +
#7 E-MPM 7 + + + - - + +
#8 E-MPM 8 + + + - - + +
#9 E-MPM 9 + + + - - + +
#10 E-MPM 10 + + + - - + +
#11 E-MPM 11Δ* +/- + + - - + +
#12 E-MPM 12 + + + - - + +
#13 E-MPM 13Δ* +/- + + - - + +
#14 E-MPM 14Δ + +/+ + - - + +
#15 E-MPM 15Δ +/+ +/+ + - - + +
#16 E-MPM 16
Δ* 
progressed + + ++ - - ++ +/-
#17 E-MPM 17
Δ 
progressed + + ++ - - ++ +/-
#18 HG E-MPM 1 - - ++ +f + +++ +f
#19 HG E-MPM 2 - + +++ - - +++ -
#20 S-MPM 3Δ -/- -/- - +++ +++ ++ -
#21 S-MPM4 Δ -/- -/- - +++ +++ + -
exp/act: expression/activation;
+/na: activation not achievable in fresh omentum samples;
+/-: expressed but not activated;
+/+: expressed and activated;
f: focal expression
ΔVEGFR2 and Met activation was investigated in snap-frozen fresh surgical samples;
*Fresh samples used for primary cell cultures
Cases 16 and 17 were defined as progressed because they showed a greater degree of malignancy than E-MpM cases #1-15, 
but were less malignant than the high-grade (HG) E-MpM cases #18 and #19.
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Figure 1: IHC findings. The figure compares a classic E-MpM (#1, Table 1) and one progressed E-MpM case (#17, Table 1) with two 
HG E-MpMs (#18 and #19, Table 1) and two S-MpMs (#20 and #21, Table 1). The classic E-MpM is characterised by a positive triple 
immunophenotype including VEGFR2, c-MET and E-cadherin, whose intensity and the number of immunolabelled cells decreases in the 
progressed case, become even less in the HG E-MpM, and disappear in the S-MpM. The reverse is true in the case of c-MYC, EZH2 and 
Mib-1, which decorate an increasing number of cells going from E-MpM to HG E-MpM. SLUG is constantly negative. On the other hand, 
S-MpM always has a negative triple immunophenotype and c-MYC immunostaining, but show SLUG positivity, and the expression of 
EZH2 and Mib-1 are similar to that in HG E-MpM. S-MpM3 has one pleomorphic and one spindle area (identified by parentheses). The 
image gallery of three additional cases of E-MpM (#11, #13 and #16) shown in Supplementary Figures 4, 5 and 7 shows that VEGFR2 
/c-MET and c-MYC/EZH2 immunoprofiles are superimposable in the surgical specimens and their corresponding cell lines. Original 
magnifications: 50X, 100X and 200X (as indicated in each figure).
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pluripotency factor [22], its ability to interact with EZH2 
[23] and to facilitate an epithelial phenotype and MErT (at 
least in mouse) [34].
miRNA 17-5p in situ hybridisation
As the observed modulation of c-MYC in E-MPMs 
and S-MPMs paralleled the level of miRNA 17-5p, we 
used ISH to investigate miRNA 17-5p expression in two 
cases of E-MpM (#1 and #11, Table 1) and one of S-MpM 
(S-MpM3, case #20, Table 1). This miRNA belongs to 
a cluster of miRNAs in human chromosome 13 that has 
been reported to be activated by c-MYC [35]. The two 
E-MpMs expressed high levels of miRNA 17-5p, with 
granular cytoplasmic expression in less than 25% of the 
tumoral cells and signal intensity ranging from moderate to 
strong (score ≥6), whereas no signal was expressed by the 
S-MpM (Figure 2A). These findings complement previous 
observations [35] and reinforce the idea that miRNA 17-5p 
in E-MpMs has oncogenic activity supporting the capacity 
of miRNAs to influence tumorigenesis in a cell-specific 
manner [36].
Biochemistry
Using the cryopreserved material obtained from 
each halved surgical sample before fixation, we used 
Western blotting (WB) to confirm MET and VEGFR2 
expression, and interrogate the activation status of c-MET 
(Figure 2B) and VEGFR2. Unexpectedly, very little or 
no activation of VEGFR2 was observed (Figure 2C). 
To address this issue, we first investigated VEGFR2/
MET co-immunoprecipitation in order to explore the 
hypothesis of VEGFR2 silencing- induced phosphatase-
mediated MET up-regulation [37]. As both analyses 
were unsuccessful (data not shown), we made in vitro 
analyses of cells obtained from frozen surgical material 
(see Figure 4, VEGFR2 switching off) in order investigate 
possible stemness in E-MpMs. Recent studies have shown 
that sunitinib-mediated VEGFR2 silencing participates 
Figure 2: ISH, biochemical and Immunofluorescence findings. A. The positive miRNA-17-5p ISH signal seen as brown dots 
localised in the cytoplasm of two E-MpMs (#1 and #11) is absent in the S-MpM (#3). B. MET WB analyses of the frozen material of the 
E- and S-MpMs (CTR+: A431 cell line) indicated in Table 1. C. Notice the absence or very low activation of VEGFR2 (as demonstrated 
by the Proteome Profiler™ Array readouts). D. The human pluripotent stem cell array confirmed the presence of E-cadherin and VEGFR2 
(cases #1, #2, #3 and #17) and revealed GATA-4 expression in E-MPMs #14 and #15. Unlike IHC, the stem cell array showed that 
the E- and S-MpMs (#3 and #4) expressed E-cadherin. This discrepancy may be attributable to a difference in the E-cadherin epitopes 
recognised by the IHC antibody (clone NCH-38, M3612, Dako) and the R&D E-cadherin antibody present in the array but, as both 
antibodies are patent protected, no information is available regarding the epitopes used as immunogens. E. E-cadherin (red) and VEGFR2 
(green) immunofluorescence highlights the hybrid phenotype (image 3 and inset) and the heterogeneity of E-MpM (images 1, 2 and 3). F. 
E- and P-cadherin co-expression and beta catenin membraneous decoration in serial sections of E-MpM #14. See text for further details. 
Original magnifications: 20X, 25X, 40X and 400X (as indicated in each figure).
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in regulating pluripotency in embryonic stem cells [38] 
and triple-negative breast cancer [39], and that a stable 
mesothelioma cell line derived from a patient over-
expressing VEGFR2 and c-MYC had stem-like traits [15].
Human pluripotent stem cell array
Pluripotent stem cell array analysis of the 
frozen material also used for the WB experiments 
revealed three factors in a ground state and therefore 
characteristics of CSCs: VEGFR2, which was expressed 
in E-MpM; E-cadherin, a MErT/EMT regulator that was 
shared by E-MpMs and S-MpMs despite its irrelevant 
immunophenotypical expression in S-MpMs; and GATA4, 
a lineage control transcription factor that activates or 
represses depending on the cell context [40, 41] and was 
restricted to two E-MpM cases (#14 and #15, Table 1, 
Figure 2D).
Together with the immunophenotype data, the stem 
cell array readouts pointed at E-cadherin as a stemness 
regulator (attributable to its ability to form cell-cell 
adhesion exchanges) [19], and support a pluripotency-
related role of dephosphorylated VEGFR2.
Hybrid immunophenotyping
In the light of the recent suggestion that the hybrid 
epithelial/mesenchymal (E/M) phenotype plays a key 
role in stemness as well as in MErT and EMT [6], we 
applied IHC and immunoflourescence to investigate the 
distribution of E-cadherin and VEGFR2 in individual 
E-MpM tumoral cells of the histological fixed samples.
The IHC and immunofluorescence analyses showed 
that, although some cells were decorated by E-cadherin or 
VEGFR2 alone, a considerable number co-expressed both 
markers (case #1, Table 1, Figure 2E and Supplementary 
Figure S3). This confirms the hybrid phenotype, highlights 
E-MpM heterogeneity, and suggests that the tumour 
may endow the cells with some of the characteristics of 
stemness and plasticity.
Furthermore, as it has been shown that P-cadherin 
expression is crucial to identifying the intermediate EMT 
state and cells with CSC properties when concomitantly 
expressed with E-cadherin [42], we investigated our samples 
using P-/E-cadherin antibodies and broadened the panel to 
include beta-catenin. P-/E-cadherin immunodecoration and 
immunofluorescence co-labelling proved to be restricted 
to E-MpMs and, once again, had a patchwork distribution 
and beta-catenin immunostaining revealed membrane 
expression, as previously reported [24] (Figure 2F).
Taken together, these findings confirm that the EMT 
in cancer has features of plastic process with multiple 
intermediate states rather than a “all or nothing” response 
[6], and support the idea that E-MpM is governed by its 
conversion to MErT.
Interestingly, the two cases expressing GATA4 
as revealed by the pluripotent stem cell array (#14 and 
#15, Table 1) had a well-developed stromal component 
that was enriched in cancer-associated fibroblasts 
(CAFs) expressing smooth muscle actin (SMA) [43] 
and characterised by SLUG decoration. They also had 
a tumoral stromal component in which single cells 
expressed lower levels of E-cadherin and P-cadherin, 
and showed nuclear GATA4 immunoreactivity, findings 
that were confirmed by the co-immunofluorescence 
analysis (Figure 3). The same immunostaining pattern 
was seen in two other cases (#6 and #7, Table 1) with a 
well-developed, multifocal stromal component revealed 
by hematoxylin and eosin. It is worth noting that FISH 
analysis showed that all four cases had a diploid profile 
in the CAF component (not shown), unlike the tumoral 
cells that presented at least one FISH abnormality 
(Supplementary Table S1).
Cell cultures
In order to investigate stemness and plasticity 
further, we used short-term cultures and stable cell 
lines obtained from the same surgical specimens as 
those analysed by means of IHC, immunofluorescence, 
biochemistry and the pluripotent stem cell array.
Characterisation of two short-term cell lines and one 
spontaneous stabilised cell line
Starting from fresh E-MpM surgical samples, two 
short-term cell lines (STC1 and STC2, corresponding to 
E-MpM cases #11 and #13, Table 1) and one spontaneous 
stable cell line (SSL1, corresponding to case #16 
E-MpM) were established, characterised, and used in in 
vitro experiments. STC1 (Supplementary Figure S4) and 
STC2 (Supplementary Figure S5) both consisted of large, 
round, epithelial-like cells, and had an immunophenotype 
that was fully consistent with E-MpM, except for the 
activation of VEGFR2 shared by both cell lines and SLUG 
expression restricted to STC1 (Supplementary Figure S6). 
The spontaneously obtained SSL1 cell line was mainly 
made up of spindle-shaped cells but also included cells 
with epithelioid features (Supplementary Figure S6). Its 
immunophenotype was consistent with E-MpM in terms 
of c-MET, c-MYC and EZH2 expression, but E-cadherin 
levels were low, SLUG was expressed, and there was 
no VEGFR2 expression (Supplementary Figure S6-S7). 
This phenotype, which strongly suggested an attenuated 
epithelioid phenotype consistent with MErT, and a 
transition towards an intermediate rather than a full EMT 
phenotype, was not unexpected as the cell line was derived 
from case #16, the most “progressed” of the E-MpMs.
As this intermediate (epithelioid/mesenchymal) 
phenotype was shown by the cells immediately after 
seeding and was maintained during the passages (in 
terms of cytokeratin CAM 5.2/CD44 co-expression, data 
not shown), we concluded that SSL1 is a stable hybrid 
cell population co-expressing epithelial (CAM 5.2)/
mesenchymal as well as CSCs (CD44) markers. It is 
worth noting that compared to the surgical specimens 
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from which they were derived the cell lines had a more 
mixed profile including features of both HG E-MpM and 
S-MpM. These changes probably represent an incomplete 
switch towards a mesenchymal phenotype endowed with 
high degree of plasticity because of the partial EMT [6].
Stemness and plasticity experiments
Given the characteristics of the short-term 
cultures and the stable cell line, we used the first (which 
showed activated VEGFR2) to investigate whether 
phosphorylation had an impact on stemness, and the 
second (which had more mesenchymal traits) to verify the 
more metastable plasticity of E-MpMs.
The pharmacological switching off of VEGFR2
STC1 and STC2 were treated for 24 hours with 
bevacizumab (a specific VEGFR2 inhibitor) and sunitinib 
(an inhibitor of the PDGFR family, VEGFR2 and c-MET). 
In addition to reduce the activation of their targets 
(stronger in sunitinib respect to bevacizumab treatments, 
Figure 4A), both drugs induced an increase in SLUG 
(Figure 4B). Overall, the experiments demonstrated that 
VEGFR2 activation induces SLUG degradation, and 
that its switching off leads to a more primitive CSC-like 
status as shown by the increase in SLUG protein and RNA 
(Figures. 4B and 4C), even if this did not result in full 
EMT. Further support to the concept of incomplete EMT 
was given by the retained epithelioid morphology of STC1 
and STC2 after VEGFR2 had been switched off (compare 
Figure 4D with Figure 5).
CSC array-based comparative analysis
As pluripotent genes are critical for maintaining 
pluripotency, we used CSC array to compare the number 
of CSC genes between an E-MpM and glioblastoma 
cell line (which is known to harbour a high percentage 
of CSCs) [44] as a means of further confirming that 
E-MpMs are enriched in CSC cells. The results showed 
the transcriptional enrichment of genes known to be over-
expressed in mesenchymal stem cells (Thy1, Fgfr2, Axl, 
Alcam and CD105) and genes involved in controlling 
pluripotency (c-MYC and ID1) in STC1 (Figure 4E).
MpM plasticity
After HGF stimulation, SSL1 showed a decrease of 
EZH2 expression (Figure 5A). Conversely, the treatment 
of SSL1 with TGFbeta1/IL1 induced an increase in EZH2 
(Figure 5B). On the contrary, c-MYC levels remained 
stable during both treatments.
Figure 3: IHC and IF characterisation of stromal and tumoral cells in one GATA-4-positive case. E-MpM #14 (Table 1) 
showed a well-developed stromal component enriched in cancer-associated fibroblasts (indicated by asterisks) expressing smooth muscle 
actin A. and SLUG B. Note that the stroma-embedded, epithelioid-like tumoral component (indicated by circles) showed strong GATA-4 
nuclear immunoreactivity C and D. and lower E-cadherin (blue circle, E. and P-cadherin (blue circle, F. expression than the surrounding 
papillary/row featuring epitheliod tumoral cells (red circles, 3E and 3F). The results were confirmed by immunofluorescence G. Similar 
results were obtained in three other E-MpMs (#6, #7 and #15, Table1) that showed GATA-4 expression. Original magnifications: 40X, 50X 
and 100X (as indicated in each figure).
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Overall, these findings are in keeping with the 
idea that MErT and EMT are transient and reversible 
conditions, and that mesothelioma cells can feature a 
dynamic phenotype that allow them to shift from more 
epithelioid (MErT) or more mesenchymal traits (EMT) 
and back.
EZH2 pharmacological inhibition by GSK 126
To verify whether EZH2 inhibition could be 
therapeutically exploited in E-MpM, we treated SSL1 
(the spontaneous stabilised cell line obtained from an 
epitheliod mesothelioma) with the EZH2 inhibitor GSK 
126, which lead to a reduction in growth and a decrease in 
SLUG transcription (Figure 5C).
DISCUSSION
Most previous studies have focused on the role of 
EMT and very few have investigated MErT, particularly 
in the context of mesothelioma. Our findings provide 
evidence that E-MpM is enriched in stemness and 
plasticity governed by an MErT process.
Figure 4: Switching off VEGFR2 regulates the stemness traits of E-MpMs. A. STC1 was treated with bevacizumab and 
sunitinib for 24 hours. The relatives changes in VEGFR2 and PDGFRB activation were calculated using ImageJ software by normalising 
the corresponding dots in treated and untreated samples. After bevacizumab treatment, PDGFRB and VEGFR2 respectively showed 
activation (from 8.25 to 9.26) and deactivation (from 6.92 to 6.40). After sunitinib treatment, both PDGFRB and VEGFR2 were completely 
de-phosphorylated. Both drugs induced an increase in SLUG (the relative changes in SLUG expression were calculated using ImageJ 
software with tubulin beta3 as a housekeeping protein (shown in the figure as normalised SLUG/tubulin beta3). B. As the increase of 
SLUG transcription measured in STC1 by quantitative PCR is small, it can be assumed that it is unable to induce a complete EMT C. 
an assumption that is supported by the similarly treated STC2 (4C) and the fact that STC1 retained its epithelioid morphology D. E. The 
transcriptional level of various genes known to be involved in stemness was investigated by comparing STC1 with the U-87 glioma cell line 
(a tumour known to have a strong CSC component). The complete gene list is given in RT2 Profiler PCR array cancer stem cells (Qiagen, 
Cat. No. PAHS-176Z). Hprt was chosen as the reference house-keeping gene because its transcription level was similar in STC1 and U-87 
(i.e. a cycle threshold of about 24 in both lines). The most significantly over-transcribed genes are shown in the figure. The results underline 
the transcriptional enrichment of mesenchymal (Thy1, FGFR2, AXL, ALCAM and CD105) and staminal genes (c-MYC and ID1) in STC1 
in comparison with U-87. Original magnification 10x; scale bar 10 μM (inset).
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Figure 5: HGF, TGFβ1/IL1b and GSK 126 treatment. A. SSL1 was starved by means of 48-hour serum restriction, and then 
treated with recombinant HGF (20 ng/mL) for 30 minutes. Despite the minimal morphological changes, the WB readouts showed a 
decrease in EZH2 while c-MYC remained stable. Original magnification 20x; scale bar 100 μM (inset). B. SSL1 was starved by means of 
48-hour serum restriction, and then treated with recombinant TGFβ1 (0.5 ng/mL) and IL1b (2 ng/mL). After treatment, the cells acquired 
more spindle-shaped features, and WB revealed a marked increase in EZH2. c-MYC remained stable as after HGF treatment. Original 
magnification 20x; scale bar 100 μM (inset). The relative changes in EZH2 and c-MYC expression were calculated using ImageJ software 
with actin as a housekeeping protein (shown in the figure as normalised EZH2/actin or c-MYC/actin). C. SSL1 was treated with GSK 
126 as shown in the figure. After seven days of treatment, the cells acquired a more elongated and bi-polar morphology. After 10 days of 
treatment, a reduction in cell growth and SLUG transcription were respectively observed by means of cell counts and quantitative PCR. 
Original magnification 20x; scale bar 10 μM (inset).
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MpM arises from the mesothelium, a mesenchymal 
tissue derived from the celomic epithelium expressing 
WT1 [45] that has an intrinsic ability to differentiate 
along both the epithelial and mesenchymal axes. This 
trait is preserved in MpM. We began our analysis by 
investigating the status of c-MET, which is known to 
favour mesenchymal-epithelial transition [17], in a 
series of surgical specimens. The expression/activation 
of c-MET proved to be restricted to E-MpM and, focally 
and to a very little extent, its direct high-grade (HG) 
progression. The HGF/c-MET activation loop, that 
possibly reflects the cell response to asbestos-induced 
DNA damage, triggers mesothelial cell reprogramming. 
This phenomenon may directly affects bivalent 
mesothelial cells [45] but also mesothelial cells that have 
acquired a myofibroblast phenotype after a first EMT 
round triggered by an inflammatory asbestos-induced 
repair response [46].
The aim of the subsequent surgical specimen-
based analyses was to identify the interactions between 
chromatin-modifying factors, TFs, adhesion molecules 
and RTKs, and showed that EZH2 was increasingly 
expressed from E-MpM to HG E-MpM and S-MpM, 
whereas c-MYC, E-cadherin and VEGFR2 expression 
was restricted to E-MpMs. The expression of c-MYC 
not only increased within the E-MpM spectrum, but 
also closely correlated the expression of miRNA 17-
5p, a non coding c-MYC regulated RNA that has been 
reported to contribute to highly malignant tumours in 
humans and promote stem cell properties in mice [37]. 
On the basis of these findings, and bearing in mind the 
spectrum-wide role played by c-MYC [15, 22, 23, 28, 
36] and the typical wide spread presentation of MpM, 
we hypothesised that c-MYC may facilitate and maintain 
[47] the CSC-like status of E-MpM cells during their 
characteristic metastatic-like seeding of the abdominal 
cavity [11] that acts as hospitable soil similar to an 
enlarged niche [48].
Further robust support of the stemness of E-MpM 
was given by the pluripotent stem cell array readouts, 
which allowed us to investigate the existence of the hybrid 
E-cadherin/VEGFR2 phenotype that may provide E-MpM 
cells with stemness and plasticity by exploiting epithelial-
related cell-cell adhesion and mesenchymal-related 
migration. The membranous decoration of E-cadherin, 
P-cadherin [6, 42], and beta-catenin [24] also supported 
the presence of the E/M phenotype and its association with 
stemness and plasticity (Figure 3).
The results also suggested that the progression 
to HG E-MpM may occur in two different ways. In the 
first case, which may correspond to that described as 
transitional or, more probably HG/undifferentiated MpM 
[11], the E-MpM cells retain the immunophenotypical 
profile but activate c-MYC and EZH2. This correlates 
with a high tumor proliferation index (Ki-67) and, due 
to EZH2 overexpression, a decrease in E-cadherin (Table 
1, cases #18 and #19) [49]. The hypothesis of direct 
progression is supported by evidence of E-MpM cases 
with increasingly malignant characteristics, such as our 
cases #16 and #17. The second type of progression is the 
progression to S-MpM. In this case, c-MYC is replaced by 
the expression of the EMT regulators SLUG and TWIST, 
with down regulation of E-cadherin, VEGFR2 and c-MET. 
The modulation of the immunoprofile is in line with the 
ability of c-MYC to counteract the EMT pathway [50] 
and, as happens in embryonic stem cells [51], interfere 
with the epigenetic regulation of CSCs [52].
Overall, our findings suggest a model in which the 
reprogramming is driven by MErT in E-MpM and by EMT 
in S-MpM (Figure 6). During such reprogramming, it is 
thought that the interaction between TFs and the epigenetic 
regulators is essential to induce the decommission of their 
poised status in order to activate/repress transcriptionally 
the specific context-dictated epithelial/mesenchymal 
genes. Here, the c-MYC and EMT regulators representing 
TFs and the histone protein EZH2 acting as a surrogate of 
epigenetic regulators, while P-/E-cadherin and VEGFR2 
cooperate in giving a hybrid phenotype that endows 
E-MpM cells with stem cell characteristics.
In addition to E-/P-cadherin and VEGFR2, two 
our E-MpMs investigated by means of pluripotent stem 
cell array also showed the expression of GATA4, another 
stemess-related marker. The signature of these two cases 
(subsequently joined the two fixed cases #6 and #7, 
Table 1) closely mirrored that of E-MpM but they also 
had a well-developed stromal component enriched in 
CAFs expressing SLUG and TWIST, thus supporting the 
idea that CAFs may elicit the acquisition of stem-like traits 
and/or favour EMT [53, 54]. No evidence of malignancy 
of the stromal component was found in any of these cases, 
but the tumoral cells showed nuclear immunoreactivity 
when challenged with GATA 4 antibody and retained, 
albeit decreased, E-cadherin decoration. The interplay 
between GATA4 and E-cadherin is in line with the non-
canonical GATA4-type of EMT in which GATA4 triggers 
a E-cadherin-mediated redistribution that affects adhesion 
and facilitates collective cell migration without interfering 
with the RNA or protein levels of E-cadherin [55]. These 
findings further support the hybrid nature of tumoral cells 
and raise the hypothesis that the observed changes may 
represent an early phase of progression to a biphasic 
variant of MpM.
Short-term cultures allowed us to identify a 
possible unprecedented role for VEGFR2. Whilst 
canonical VEGFR2 activation is typically marked by 
SLUG degradation, VEGFR2 novel and activation-
independent activity is associated with SLUG expression 
(Figure 4). It is worth noting that the extent expression of 
SLUG was moderate, and this is in line with the partial, 
hybrid phenotype known to endow tumour cells with 
stemness [6]. These results disregard the expectancies 
generated by the recently re-proposed vascular featuring 
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immunophenotype of E-MpM (VEGFR2 expression and/
or VEGFR2/MET co-expression in E-MpM) [12] for a 
role of anti-angiogenic treatments.
The hypothesis that E-MpM is made up of cells 
with stem-like properties was also supported by the 
results obtained by applying the cancer stem cell profiler 
complemented by PCR to STC1. The readouts highlighted 
the transcriptional enrichment of genes known to be 
involved in maintaining pluripotency (c-MYC and ID1) 
[22, 56] or highly expressed in mesenchymal stem 
cells (Thy1, Fgfr2, Axl, Alcam and CD105) [57–59]. 
Furthermore, our SSL1 experiments demonstrated that 
E-MpM has a high degree of plasticity: when challenged 
with TGFβ1/IL1b, the tumoral cells acquired a more 
mesenchymal phenotype but, when challenged with HFG, 
they acquired a more epithelioid phenotype. Finally, given 
the biological characteristics of our E-MpM specimens, 
we treated the most spindle cell-enriched E-MpM-derived 
SSL1 cell line with the EZH2 inhibitor GSK 126. The 
observed reduction in cell proliferation strongly suggests 
that it is worth considering the possibility of using 
chromatin modifiers or inhibitors to treat patients with 
mesotheliomas.
On the basis of our findings as a whole, we propose 
a model in which E-MpM may be viewed as a disease 
essentially composed by cells with an hybrid phenotype 
within the MErT framework. In this model, rather than 
corresponding to a more differentiation-committed entity, 
Figure 6: Proposed E-MpM model. The model suggests that, once having overcome the senescence barrier A., (see also Supplementary 
Table S1) which per se significantly increases the yield of CSC colonies, the cells enter MErT to up-regulate pluripotency as a result of a 
c-MET/HGF loop B. The expression of c-MYC, miRNA 17-5p and E-cadherin seems to be necessary and sufficient to trigger the initial 
steps of MErT. Thereafter, the interaction of c-MYC and EZH2 (acting as surrogate epigenomic mediators determining cell fate) allows and 
maintains the hybrid E-cadherin/VEGFR2 phenotype (the hallmark of E-MpM) and the concomitant expression of P- and E-cadherin. As 
demonstrated by our cell culture experiments, these hybrids are endowed with stemness traits and a high degree of plasticity. During disease 
progression, in keeping with the plasticity of MErT/EMT processes, the hybrid MErT phenotype can progress to high-grade E-MpM or 
acquire the full EMT leading to S-MpM. This parallels the decommissioning c-MYC, which is replaced by EMT regulator expression 
(SLUG and TWIST). As a lineage control factor, GATA-4 may be involved in resetting progression, and be a prerequisite for biphasic 
E-MpM (E-MpM showing separated areas of both sarcomatous and epithelial elements).
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E-MpM represents a state of greater, plastic, stemness-
enriched tumoral growth that is likely to be poorly 
responsive to traditional treatment but may respond to 
epigenetic regulator inhibitors. This possibility is further 
supported by the recently reported inverse correlation 
between strong EZH2 expression and the loss of the 
chromatin modifier BAP-1 [60], whose increasingly 
deregulated nature in sporadic mesotheliomas [61] we are 
currently investigating.
MATERIALS AND METHODS
Patient samples
The case material consisted of formalin-fixed, 
paraffin-embedded (FFPE) surgical samples obtained 
from 21 previously untreated patients (who subsequently 
underwent cytoreductive surgery and hyperthermic 
intraperitoneal chemotherapy).
On the basis of the proposed TMN staging of MpM 
[62], all but one patient (case #12, Table 1) were in stage 
2 (10 patients) or 3 (10 patients). The diagnoses made 
on the basis of morphological and immunophenotypical 
criteria (calretinin, WT1, cytokeratin 5/6) [11] as well as 
podoplanin as proposed in the WHO classification [10] 
were 17 E-MpMs (#1-17, Table 1), two HG E-MPM 
(#18-19, Table 1) and two S-MpMs (#20-21, Table 1). 
Frozen material was available for biochemical analyses 
of 11 patients, three of whom also provided additional 
fresh material for the primary cell culture experiments. 
Finally, three FFPE omentum samples were obtained 
from unrelated MpM patients. Written informed consent 
was obtained from all of the patients in accordance with 
the regulations of the Ethics Committee of the Fondazione 
IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Immunohistochemistry (IHC), fluorescence in situ 
hybridisation (FISH) and PCR assessments of p16, 
NF2 and BAP1
All of the cases were analysed for P16 and NF2 
gene status by FISH, P16 gene promoter methylation by 
means of PCR, and p16 and BAP1 expression by means 
of IHC. The methodological details and results are given 
in the supplementary material and Supplementary Tables 
S1 and S2. In brief, 18 cases had overcome senescence: 
12 cases showed the inactivation of P16 (detected by 
means of FISH and/or promoter methylation and/or IHC), 
6 cases the loss of BAP1 and 1 case the loss of BAP1/
NF2. The remaining three cases showed the loss of BAP1, 
together with the loss of NF2 in one case (Supplementary 
Table S1).
Immunohistochemistry
Representative 2 μm sections obtained from FFPE 
tumoral samples of all of the cases were selected and 
phenotyped. The antibodies and experimental conditions 
used to detect the expression of VEGFR2, c-MET, 
E-cadherin, c-MYC, EZH2, Ki67, SLUG, TWIST, 
P-cadherin, beta catenin, 1A4 actin, GATA4, p16, BAP1 
and INI1 are shown in Supplementary Table S2.
In situ hybridization (ISH)
The c-MET RNA, VEGFR2 RNA and microRNA 
(miRNA) 17-5p ISH methods are described in the 
supplementary material.
Immunofluorescence
The co-expression of E-cadherin, VEGFR2, 
E-cadherin/P-cadherin and E-cadherin/GATA4 was 
investigated by means of immunofluorescence. The 
primary antibodies were diluted and retrieved as described 
in the supplementary material, and the slides were then 
incubated for one hour at room temperature with the 
specific secondary Alexa Fluor antibody (Alexa Fluor 488 
and 546, Thermo Fischer Scientific, MA, USA).
Western blotting and phospho-Receptor tyrosine 
kinases (RTKs) array
All of the analyses were made using frozen material 
taken from the patient samples (Table 1). VEGFR2 
activation was investigated using a phospho-RTK 
array kit (Proteome Profiler™ Array, ARY001B, R&D 
Systems, Minneapolis, MN, USA) and 1 mg of protein 
lysate in accordance with the manufacturer’s protocol. 
The Western blot (WB) conditions used to detect c-MET, 
c-MYC, EZH2, SLUG and β-actin expression and c-MET 
activation are shown in Supplementary Table S3.
Protein amounts were evaluated using ImageJ 
software in accordance the manufacturer’s instructions.
Human pluripotent stem cell array
Stem cell marker expression was assessed by 
means of a human pluripotent stem cell array kit (Cat. 
No. ARY010 R&D Systems) in accordance with the 
manufacturer’s instructions.
Primary cell cultures
Establishment and characterisation
Two short-term cell cultures and one stable cell line 
were obtained starting from the fresh material of three 
patients (Table 1) and characterised by means of WB, 
flow cytometry and IHC as described in the supplementary 
material.
RNA analyses
RNA extracted from mesothelioma cell cultures and 
the U-87 glioma cell line (American Tissues Cell Cultures, 
Cat. No HTB-14), was quantified and retro-transcribed 
as described in the supplementary material. The cancer 
stem cell genes were investigated using RT2 Profiler PCR 
array cancer stem cells (Cat. No. PAHS-176Z, Qiagen, 
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Hilden, Germany) in accordance with the manufacturer’s 
guidelines. Selected genes were also investigated by 
means of real-time PCR as described in the supplementary 
material.
Bevacizumab and sunitinib treatments
Bevacizumab (Avastin, Roche, Basel, Switzerland) 
25 mg/mL was diluted to 1 mg/mL in cell culture medium; 
sunitinib (Cat. No. S1042, Sellek, Munich, Germany) was 
diluted to 10 mM in DMSO, and 10 μM used for treatment. 
After 24 hours of treatment, the proteins were extracted as 
described in Supplementary Table S2, and 20 μg of the cell 
extract was investigated by means of WB using the SLUG, 
actin and Tubulin beta3 antibodies (Supplementary Table 
S3). VEGFR2 and PDGFRB activation was investigated 
using a phospho-RTK array kit (Proteome Profiler™ 
Array, ARY001B, R&D Systems).
Hepatocyte growth factor (HGF) treatment
Before treatment, the cells were deprived of serum 
for two days. Recombinant HGF (Cat. No. H1404, 
Sigma-Aldrich, Saint Louis MO, USA) was added in 
cell culture medium at a concentration of 20 ng/mL [63] 
for 30 minutes, and then removed. The proteins were 
extracted from untreated or HGF-stimulated cells after 48 
hours, and investigated by means of WB as described in 
Supplementary Table S3.
Transforming growth factor beta1 (TGF-b1) / 
interleukin 1b (IL-1b) treatment
After being deprived of serum for two days, the cells 
were treated for 72 hours with a combination of human-
recombinant TGF-β1 0.5 ng/mL (R&D Systems) and IL-
1b 2 ng/mL (Peprotech, Rocky Hill, NJ, USA) [64]. The 
proteins were extracted and were investigated by means of 
WB as described in Supplementary Table S3.
GSK 126 treatment
GSK 126 (Cat. No. S6071, Sellek) was diluted to 
5 mM in DMSO and used at doses of 2, 5, 10 and 15 
μM. After treatment, the cells were detached using a 1% 
trypsin-EDTA solution (Cat. No. 15400, Thermo Fischer 
Scientific), and counted using a standard trypan blue assay. 
RNA was extracted from the treated and untreated cells, 
and 500 ng were retro-transcribed to cDNA. SLUG and 
beta 2 microglobulin cDNAs used as endogenous controls 
was relatively quantified as described in supplementary 
materials.
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